Gold futures traded lower on Wednesday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Sema4 Holdings
- The Trade: Sema4 Holdings Corp. (NASDAQ:SMFR) Director Eli Casdin acquired a total of 11,437,500 shares at an average price of $4.00. To acquire these shares, it cost $45.75 million.
- What’s Happening: Sema4 is expected to release financial results for the first quarter of 2022 on Thursday, May 12, 2022.
- What Sema4 Holdings Does: Sema4 Holdings Corp is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights.
Viking Therapeutics
- The Trade: Viking Therapeutics, Inc. (NASDAQ:VKTX) Director Matthew Foehr acquired a total of 45,000 shares at an average price of $2.47. The insider spent around $111.19 thousand to buy those shares.
- What’s Happening: Viking Therapeutics recently reported worse-than-expected Q1 EPS results.
- What Viking Therapeutics Does: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders.
Also check this: Executives Buy More Than $90M Of 4 Stocks
Don’t forget to check out our premarket coverage here .
Tempest Therapeutics
- The Trade: Tempest Therapeutics, Inc. (NASDAQ:TPST) Director Thomas Woiwode acquired a total of 2,118,644 shares at an average price of $2.36. To acquire these shares, it cost around $5 million.
- What’s Happening: Tempest Therapeutics recently announced $15 million of private placement financing.
- What Tempest Therapeutics Does: Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
